Evidence map›Paper›PMID 34070150›Full record

ArticleMolecules (Basel, Switzerland)2021

Activity Components from

Yumeng Zhang, Guohui Shi, Zhonghua Luo, Jiewen Wang, Shao Wu, Xiaoshu Zhang, Yuqing Zhao

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Therapeutic Potential ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Mechanistic Exploration ofBioMed research international · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yumeng ZhangSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Guohui ShiSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhonghua LuoSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jiewen WangSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shao WuSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xiaoshu ZhangSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuqing ZhaoSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic fibrosis would develop into cirrhosis or cancer without treating. Hence, it is necessary to study the mechanism and prevention methods for hepatic fibrosis.

Indexed as

Molecular Targeted TherapyApoptosisCell CycleCell LineCell ProliferationChromatography, High Pressure LiquidGene OntologyGynostemmaHumansLiver CirrhosisPlant ExtractsProtein Interaction MapsgypenosidePlant ExtractsG. pentaphyllumhepatic fibrosisnetwork pharmacologyPI3K/Akt signaling pathway

Identifiers

PMID34070150
PMCPMC8158484
OpenAlexW3162342463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.